Bioxcel Therapeutics: RSI Overbought and KDJ Death Cross Triggered on 15min Chart

Bioxcel Therapeutics's 15-minute chart has recently triggered an RSI Overbought condition and a KDJ Death Cross at 08/18/2025 09:45. This suggests that the stock price has experienced a rapid increase, exceeding fundamental support levels, and is now exhibiting a downward momentum shift. As a result, there is potential for further decreases in the stock price.

Bioxcel Therapeutics' (BTAI) stock has been under the spotlight recently, with technical indicators suggesting a potential downward trend. On August 18, 2025, at 09:45, the 15-minute chart for Bioxcel Therapeutics triggered an RSI Overbought condition and a KDJ Death Cross. These indicators point to a rapid increase in the stock price, exceeding fundamental support levels and shifting momentum towards the downside.

The RSI (Relative Strength Index) measures the speed and change of price movements, and an RSI Overbought condition indicates that the stock may be overvalued. The KDJ indicator, which measures momentum, has also triggered a "death cross," further reinforcing the bearish signal [1].

Bioxcel Therapeutics has been experiencing significant volatility, with a remarkable 66.79% intraday surge on August 8, 2025, reaching $2.285 and trading near its 52-week high of $13.36. This surge was driven by the completion of the Phase 3 SERENITY At-Home trial, which evaluated the safety of BXCL501—a sublingual film formulation of dexmedetomidine—for at-home treatment of agitation in bipolar and schizophrenia patients [2].

Despite the drug's known safety risks, including hypotension and QT interval prolongation, investors are optimistic about the potential upside. However, technical indicators suggest caution. The Relative Strength Index (RSI) at 18.75 indicates oversold conditions, while the MACD histogram (-0.072) shows divergence. The stock is above the 200-day moving average, a positive sign for momentum traders, but remains 67% below its 52-week high [1].

Options traders have identified two key contracts to navigate BTAI's volatility, with the BTAI20260116C2.5 call option offering high gamma for a potential short-term rebound and the BTAI20260116C3 call option being speculative due to low liquidity [1].

Bioxcel Therapeutics stands at a critical juncture as the SERENITY At-Home trial nears its data-readout phase. The 66.79% intraday surge reflects a mix of optimism and speculative fervor, but technical indicators suggest caution. The stock's ability to hold above $2.50 (30-day support) will be a key near-term test, while a sustained break above $2.60 (intraday high) could reignite momentum. Investors should monitor the topline data for statistical significance and FDA alignment, as these will determine whether this rally is a fleeting bounce or the start of a broader biotech re-rating [2].

In conclusion, Bioxcel Therapeutics' recent technical indicators suggest a potential downward trend in its stock price. While the company's clinical trials and market opportunities have bolstered investor confidence, the RSI Overbought condition and KDJ Death Cross indicate that the stock may be overvalued and could experience further decreases. Investors should monitor the company's progress closely and consider the implications of these technical signals.

References:
[1] https://www.ainvest.com/news/btai-23-35-surge-volatility-catalyst-unleashed-biotech-playmaker-defies-52-week-lows-spark-intraday-frenzy-2508/
[2] https://www.ainvest.com/news/top-penny-stocks-watch-ainos-sg-blocks-bioxcel-therapeutics-2508/